Ckdb-501A
Post-stroke Upper Limb Spasticity
CKD Bio CorporationPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Post-stroke Upper Limb Spasticity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
INCOBOTULINUMTOXINA Merz Pharmaceuticals GmbH | Phase 3 | BB |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →